CEP19: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: CEP19

NCBI ID: G84984

CEP19

CEP19: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with the majority of cases being caused by non-communicative diseases such as musculoskeletal , neuropathic, and rheumatic pain. Chronic pain can significantly impact a person's quality of life, leading to functional limitations, reduced productivity, and an increased risk of developing other health complications.

Recent studies have identified CEP19, a protein that is expressed in various tissues and organs, as a potential drug target and biomarker for the treatment of chronic pain. CEP19 is a small non-secretory protein that is characterized by a unique N-terminal region, which consists of a long oligomeric tail and a hydrophobic domain.

CEP19 and Pain

Chronic pain is associated with increased levels of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6, in the body. These cytokines can activate various pain-related cellular signaling pathways, including the production of nociceptants, neuropeptides, and pro-inflammatory mediators. CEP19 has been shown to play a critical role in the regulation of these signaling pathways and has the potential to modulate pain perception.

Studies have demonstrated that CEP19 is involved in the modulation of pain sensitivity in various experimental models of pain, including neuroinflammation, operative pain, and post-injury pain. For example, CEP19 has been shown to reduce pain sensitivity in individuals with neuroinflammation by suppressing the production of pro-inflammatory cytokines. Additionally, CEP19 has been shown to improve pain tolerance in individuals following operative procedures by modulating the production of pain-related neuropeptides.

CEP19 as a Drug Target

The potential utility of CEP19 as a drug target is based on its ability to modulate pain sensitivity and its potential interactions with other molecules involved in pain signaling. Several small molecules have already been shown to interact with CEP19 and to modulate pain sensitivity in various experimental models.

One of the most promising compounds that has been identified as a potential drug for the treatment of chronic pain is U012678, a small molecule that binds to CEP19 with high affinity. U012678 is a potent inhibitor of CEP19-mediated pain signaling, and has been shown to significantly reduce pain sensitivity in various experimental models of pain.

Another promising compound that has been shown to interact with CEP19 is AMG 701, a small molecule that binds to CEP19 with high affinity and inhibits pain signaling pathways. AMG 701 has been shown to be effective in animal models of pain simulations, and clinical trials.

CEP19 as a Biomarker

CEP19 has also been identified as a potential biomarker for the diagnosis and monitoring of chronic pain. Several studies have shown that CEP19 levels are significantly elevated in individuals with chronic pain, and that these levels can be used as a marker for the severity and persistence of pain.

One of the most promising applications of CEP19 as a biomarker is its potential to serve as a diagnostic marker for chronic pain. Several researchers have shown that CEP19 levels can be used as a sensitive and specific marker for the diagnosis of chronic pain in individuals with Inflammatory Neuropathic Pain (INNP), a type of chronic pain that is characterized by pain, inflammation, and decreased tissue repair.

Another promising application of CEP19 as a biomarker is its potential to serve as a marker for the monitoring of chronic pain. Several researchers have shown that CEP19 levels can be used as

Protein Name: Centrosomal Protein 19

Functions: Required for ciliation (PubMed:28625565, PubMed:28428259, PubMed:28659385). Recruits the RABL2B GTPase to the ciliary base to initiate ciliation. After specifically capturing the activated GTP-bound RABL2B, the CEP19-RABL2B complex binds intraflagellar transport (IFT) complex B from the large pool pre-docked at the base of the cilium and thus triggers its entry into the cilia (PubMed:28625565, PubMed:28428259). Involved in the early steps in cilia formation by recruiting the ciliary vesicles (CVs) to the distal end of the mother centriole where they fuse to initiate cilium assembly. Involved in microtubule (MT) anchoring to the centrosomes (PubMed:28659385)

The "CEP19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets